IFNA2 and COVID-19: Later in the pandemic, we found that circulating autoantibodies neutralizing high concentrations of IFN-α and/or IFN-ω are found in about 10% of patients with critical COVID-19 pneumonia but not in individuals with asymptomatic infections, representing about 20% of both critical COVID-19 cases fatal COVID-19 cases [38].